Latest Medtech News
Zylox-Tonbridge and GL Capital have announced a strategic investment in LifeTech Scientific, aimed at building an integrated vascular and structural heart intervention platform in China. Through a joint vehicle, GL Lighthouse Two Investment, the two will invest about HK$1.482B ($189M) for newly issued shares equal to about 16.7% of LifeTech’s enlarged capital. Lighthouse Two would become LifeTech’s largest single shareholder. Zylox-Tonbridge holds 60% of it through an investment of about HK$889M ($113M).
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
In a related deal, GL Capital will subscribe for 39.8 million new Zylox-Tonbridge shares at HK$22 each, about 10.8% of its enlarged capital, at a 13.5% premium to the closing price on the announcement date. The proceeds will support future LifeTech investments and international business development. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech.
The pairing covers four areas: Zylox-Tonbridge’s peripheral vascular and neurovascular businesses, and LifeTech’s aortic and structural heart businesses. Both companies sell abroad. Zylox-Tonbridge reported a 349.3% year-over-year rise in revenue outside Mainland China in the first half of 2026, and LifeTech’s revenue outside Mainland China reached nearly RMB400M ($60M) in 2025, close to 30% of its total.
Zylox-Tonbridge Chairman Dr. Jonathon Zhong Zhao said combining the two would create “a more comprehensive portfolio” and new opportunities for long-term growth.
